BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » COVID-19

AASCP Hosting Lecture on Groundbreaking Trial That May Reduce Risk of Death in Severe COVID 19 Patients

January 25, 2021 By Cade Hildreth (CEO) Leave a Comment

AASCP Dr Camillo Ricordi

Famed Miami University Dr. Camillo Ricordi, M.D. to speak on Lipogems, courtesy of The American Academy of Stem Cell Physicians, this Wednesday!

MIAMI, January 25, 2021 – The American Academy of Stem Cell Physicians (AASCP) will be hosting a sought-after lecture, featuring Dr. Camillo Ricordi, Director of Diabetes Institute and Cell Transplant Center at the University of Miami. He has been investigating how umbilical Cord Stem cells affect the immune response for more than 10 years.

He will be discussing his study on Lipogems, this Wednesday, January 27, 2021 at 7:30pm (Eastern). The Zoom information to join the meeting is below. [Read more…]

Filed Under: Press Releases, Stem Cell News Tagged With: COVID-19

Sentien Biotechnologies Does First Subject with Ex Vivo MSC Therapy Against COVID-19

December 3, 2020 By Cade Hildreth (CEO) Leave a Comment

Sentien Ex Vivo MSC Therapy
Sentien Biotechnologies Does First Subject in a Phase 1/2 Trial of its Ex Vivo MSC Therapy Against Severe COVID-19 at the University of New Mexico Hospital.

LEXINGTON, MA, NOVEMBER 23, 2020 — Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced that the first subject has been enrolled in its Phase 1/2 study of SBI-101 for the treatment of severe COVID-19 at the University of New Mexico (UNM) Hospital. SBI-101, Sentien’s innovative cell-based therapy, is being evaluated in COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) requiring renal replacement therapy (RRT). [Read more…]

Filed Under: Coronavirus (COVID-19), MSCs, Press Releases Tagged With: COVID-19

Novartis Snags Exclusive Rights from Mesoblast for MSC Therapy Against COVID-Induced ARDS

November 25, 2020 By Cade Hildreth (CEO) Leave a Comment

Novartis Mesoblast Remestemcel-l
  • Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other indications
  • Addition of remestemcel-L could expand Novartis respiratory portfolio by adding potential first-in-class ARDS therapy using innovative cell-based technology with platform potential
  • Deal includes $50 million upfront cash payment and equity/share subscription, plus performance-based milestones and royalties for access to a cell-therapy based platform with worldwide rights to a range of potential indications

Basel, November 19, 2020 — Novartis announced that it entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19. ARDS is an area of significant unmet need, with an approximate 40% mortality rate with current standard of care, which includes prolonged ICU treatment and mechanical ventilation.1,2

As the potential first ARDS therapy, remestemcel-L will use mesenchymal stromal cells (MSCs), a cell-based platform technology, to treat this deadly condition and improve outcomes. Remestemcel-L is currently being studied in COVID-19-related ARDS in an ongoing 300-patient Phase III study.3 Novartis intends to initiate a Phase III study in non-COVID-19-related ARDS after the anticipated closing of the license agreement and successful completion and outcome of the current study. [Read more…]

Filed Under: Coronavirus (COVID-19), Press Releases Tagged With: COVID-19

FDA Grants Organicell Expanded Access to Treat COVID-19 Patients with Zofin(TM)

September 29, 2020 By Cade Hildreth (CEO) Leave a Comment

organicell-covid-19-zofin

Miami, FL (September 29, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted expanded access for an intermediate size population allowing its proprietary therapeutic, Zofin for the treatment of COVID-19. [Read more…]

Filed Under: Coronavirus (COVID-19), Press Releases Tagged With: COVID-19

FDA Grants RMAT to MultiStem Cell Therapy for Treatment of ARDS

September 25, 2020 By Cade Hildreth (CEO) Leave a Comment

Athersys Multistem COVID-19

ARDS program well-positioned for an expedited path to commercialization with RMAT and Fast Track designation

September 23, 2020; Cleveland — Athersys, a leading regenerative medicine company in late-stage clinical development, announced today that MultiStem® cell therapy was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for the acute respiratory distress syndrome (ARDS) program. [Read more…]

Filed Under: Cord Blood Tagged With: COVID-19, RMAT

  • 1
  • 2
  • 3
  • 4
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Cell Therapy Manufacturing Survey - Selection Criteria for Choosing a CMO Partner
    Rated 0 out of 5
    $197 $97
  • Stem Cell Fact Sheet - Types of Stem Cells and their Use in Medicine
    Rated 0 out of 5
    $10
  • Global Database of Research Supply Companies Global Database of Research Supply Companies 2021
    Rated 0 out of 5
    $39
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.